<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>mCRPC Combined Algorithm (ASCO 2025)</title>
  <style>
    body {
      font-family: Arial, sans-serif;
      margin: 40px;
      line-height: 1.6;
    }
    h1 {
      color: #333;
    }
    details {
      margin-bottom: 14px;
      border: 1px solid #ccc;
      border-radius: 6px;
      padding: 10px;
      background: #f9f9f9;
    }
    summary {
      font-weight: bold;
      font-size: 1.1em;
    }
    .subsection {
      margin-left: 20px;
      margin-top: 10px;
      margin-bottom: 10px;
    }
    .highlight {
      background: #eef7ff;
      padding: 6px;
      border-radius: 4px;
      margin-top: 5px;
      margin-bottom: 5px;
    }
  </style>
</head>
<body>

<h1>mCRPC Combined Algorithm (ASCO 2025)</h1>
<p>Interactive collapsible version based on your summarized combined algorithm.</p>

<details>
  <summary>Always (applies to all mCRPC patients)</summary>
  <div class="subsection">
    • Continue ADT indefinitely.<br>
    • Early palliative/supportive care.<br>
    • Bone protective agent if bone mets.<br>
    • Obtain germline + somatic testing (HRR, BRCA1/2, MSI/dMMR).<br>
    • Avoid PSA-only progression decisions.<br>
    • Imaging q3–6 mo (CT CAP + bone scan).<br>
    • PSMA PET only for 177Lu-PSMA eligibility.
  </div>
</details>

<details>
  <summary>A1 — Prior ADT Alone</summary>
  <div class="subsection">
    <div class="highlight"><b>BRCA1/2+</b> → PARPi + ARPI (olaparib + abi, niraparib + abi, talazoparib + enza)</div>
    <div class="highlight"><b>Other HRR+</b> → Talazoparib + enzalutamide (conditional)</div>
    <div class="highlight"><b>HRR−</b> → Abi/pred OR enzalutamide OR docetaxel</div>
    <b>Specials:</b><br>
    • Bone-only symptomatic → Radium-223<br>
    • MSI-H/dMMR → Pembrolizumab<br>
    • Indolent low-volume → Sipuleucel‑T<br>
    • Oligoprogression → MDT<br>
  </div>
</details>

<details>
  <summary>A2 — Prior ADT + ARPI</summary>
  <div class="subsection">
    <div class="highlight"><b>BRCA1/2+</b> → Olaparib monotherapy</div>
    <div class="highlight"><b>Other HRR+</b> → Olaparib monotherapy (conditional)</div>
    <div class="highlight"><b>HRR−</b> → Docetaxel (avoid ARPI→ARPI)</div>
    • Sip-T (selected), local MDT possible.<br>
    • Radium‑223 if bone‑only symptomatic.
  </div>
</details>

<details>
  <summary>A3 — Prior ADT + Docetaxel</summary>
  <div class="subsection">
    <div class="highlight"><b>HRR+</b> → PARPi + ARPI if ARPI‑naïve</div>
    <div class="highlight"><b>HRR−</b> → Abi/pred OR enzalutamide OR cabazitaxel</div>
    • Radium‑223 (bone only), pembrolizumab (MSI‑H).<br>
  </div>
</details>

<details>
  <summary>A4 — Prior ADT + ARPI + Docetaxel (Triplet)</summary>
  <div class="subsection">
    <div class="highlight"><b>PSMA+</b> → 177Lu‑PSMA‑617 OR cabazitaxel</div>
    <div class="highlight"><b>HRR+</b> → Olaparib monotherapy</div>
    • PSMA− → Cabazitaxel ± radium‑223<br>
    • MSI‑H → Pembrolizumab<br>
  </div>
</details>

<details>
  <summary>B — Neuroendocrine / Small‑Cell Variant</summary>
  <div class="subsection">
    • Cisplatin or carboplatin + etoposide (1st line)<br>
    • Carboplatin + cabazitaxel (AVPC features)<br>
    • Clinical trial preferred after platinum<br>
    • Optional: Immunotherapy + platinum maintenance, lurbinectedin, topotecan, tarlatamab
  </div>
</details>

<details>
  <summary>High-Yield Memory Lines</summary>
  <div class="subsection">
    • “Know the Past → Test the Tumor → Treat the Type.”<br>
    • BRCA: ARPI‑naïve → PARPi+ARPI; post‑ARPI → PARPi alone.<br>
    • Avoid ARPI→ARPI after failure (CABAZITAXEL wins).<br>
    • Bone-only symptomatic → Radium‑223 (not with abi/pred).<br>
    • PSMA lights the Lu → 177Lu‑PSMA‑617 after ARPI + taxane.<br>
  </div>
</details>

</body>
</html>
